Xiaoliang Jin

Xiaoliang Jin

Auto-generated profile, based on publicly available information

Xiaoliang Jin

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
TYTengteng Yao
Tengteng Yao
ZZZhe Zhang
Zhe Zhang
QLQian Li
Qian Li
RHRui Huang
Rui Huang
YHYanhong Hong
Yanhong Hong
JSJianfeng Shen
Jianfeng Shen
Tumor-specific neoepitopes are promising targets in cancer immunotherapy. However, the identification of functional tumor-specific neoepitopes remains challenging. In addition to the most common source, single-nucleotide variants (SNV), alternative splicing (AS) represents another rich source of neoepitopes and can be utilized in cancers with low SNVs such as uveal melanoma (UM). UM, the most prevalent adult ocular malignancy, has poor clinical outcomes due to a lack of effective therapies. Recent studies have revealed the promise of harnessing tumor neoepitopes to treat UM. Previous studies have focused on neoepitope targets associated with mutations in splicing factor 3b subunit 1 (SF3B1), a key splicing factor; however, little is known about the neoepitopes that are commonly shared by patients independent of SF3B1 status. To identify the AS-derived neoepitopes regardless of SF3B1 status, we herein used a comprehensive nanopore long-read-sequencing approach to elucidate the landscape of AS and novel isoforms in UM. We also performed high-resolution mass spectrometry to further validate the presence of neoepitope candidates and analyzed their structures using the AlphaFold2 algorithm. We experimentally evaluated the antitumor effects of these neoepitopes and found they induced robust immune responses by stimulating interferon (IFN)γ production and activating T cell–based UM tumor killing. These results provide novel insights into UM-specific neoepitopes independent of SF3B1 and lay the foundation for developing therapies by targeting these actionable neoepitopes.

27 July 2023 in Trends in Parasitology
Verified
Journal Article
Closed access
MLMengqi Liu
Mengqi Liu
William C. ChoWilliam C. Cho
William C. Cho
RFRobin J. Flynn
Robin J. Flynn
XJXiaoliang Jin
Xiaoliang Jin
HSHouhui Song
Houhui Song
Yadong ZhengYadong Zheng
Yadong Zheng


22 May 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
JHJie He
Jie He
RHRui Huang
Rui Huang
CZChunyan Zong
Chunyan Zong
QLQian Li
Qian Li
YWYihao Wang
Yihao Wang
JSJianfeng Shen
Jianfeng Shen
Significant progress in the application of immune checkpoint blockade (ICB) for the treatment of multiple types of cancers has been achieved, but its overall response rate and therapeutic efficacy remain unsatisfactory. To address these limitations, the identification of a combinational approach to enhance the therapeutic efficacy of ICB is needed. The activation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling is critical to the induction of antitumor innate immune responses and is a promising target for the development of combinational immunotherapy. Here, through the Connectivity Map database and a kinase inhibitor library screen using interferon-stimulated genes (ISGs) as a functional readout, we identified PIKfyve as a negative regulator of cGAS-STING signaling. The inhibition of PIKfyve by the kinase inhibitor YM201636, or genetic ablation elicited the expression of ISGs downstream of cGAS-STING and reshapes the antitumor microenvironment by recruiting CD8+ T lymphocytes. In melanoma models, PIKfyve inhibition conferred sensitivity to the combinational therapy of cisplatin and anti-PD1, which lead to a durable treatment response. Depletion of Sting or CD8+ T cells in B16F10 tumor significantly weakened the synergistic effect of PIKfyve inhibition and cisplatin. Mechanistically, PIKfyve interacts with STING to facilitate its trafficking from endosome to lysosome for degradation, thereby suppressing the STING-signaling mediated antitumor activity. These results highlight the importance of maintaining STING signaling as a direction to augment the efficacies of combinational immunotherapies.